Between the promise by President Trump and FDA Commissioner Scott Gottlieb to begin approving drugs more quickly and the 2016 passage of the 21st Century Cures Act—intended to speed along many approvals—some wonder about the negative impact on drug safety and efficacy of rapid approvals. Now, research indicates that expediting reviews for certain drugs is beneficial.
The study, published in the August issue of Health Affairs, examined all the novel drug formulations approved by the FDA from 1999 to 2012. It found that drugs approved through an expedited process offered significantly improved health gains compared to standardly-approved drugs.
The breakthrough therapy program—for drugs that target serious conditions and show a marked improvement over existing drugs in preliminary evidence—was not implemented until 2012. Therefore, the expedited drug approvals evaluated in the study took three forms: priority review, for drugs that target serious conditions and that would offer significant improvement over existing options; accelerated approval, for drugs that could provide clinical benefit for unmet medical needs; and fast-track designation, for drugs that could meet an unmet medical need and that allows the drug manufacturer to have more interaction with the FDA to expedite the process. Drugs can be assigned one or more designations.
To determine the health gains of patients after taking the drug, the researchers used a measurement known as Quality-Adjusted Life Years (QALYs). One QALY is equivalent to one year with perfect health, and a year with some impairment is measured somewhere between zero and one. The authors give this example: “four years lived in perfect health equal four QALYs. Eight years experienced with a quality of life of 0.5 per year is also equal to four QALYs.”
The team examined drugs based on drug-indication pairs, meaning that if one drug had multiple indications, each indication was studied separately. They included only drugs with at least one QALY gain estimate, giving them a total of 118 drugs, or about 30% of the novel drugs approved by the FDA in that period. Altogether, they analyzed 135 drug-indication pairs: 68 in the priority review program, 31 in the fast track program, and 17 in the accelerated approval program. Thirty drugs were in multiple programs, and 59 were in no programs.
Overall, drugs that had at least expedited designation offered health gains of 0.182 QALYs compared to standard designated drugs with gains of 0.003 QALYs. Multiple designations resulted in greater QALY gains than a single designation—0.307 compared to 0.126. Compared to drugs not in the same designation, drugs in priority review (0.175 versus 0.007 QALYs), accelerated approvals (0.370 versus 0.031 QALYs), and fast track (0.254 versus 0.014 QALYs) had greater gains.
James Chambers, PhD, MPHarm, MSc, Assistant Professor of Medicine at Tufts Medical Center Institute for Clinical Research and Health Policy Studies and lead author of the study, told Drug Topics that he was not surprised by the results. He had done research in this dataset before, and so was aware of the “distribution of health gains across new drugs.” He also added that “One thing that I took from this research is that it is uncommon for new drugs to offer very large health benefits over existing treatments. Most often, we found that new drugs offered marginal improvements, and a surprising number offered no improvement over existing treatments at all.”
Up next: What this means for the FDA's future